Probenecid
Probenecid has been studied in 1 paper since 2025: none in people yet, 1 review. No study of it in people or animals has been published yet. The newest paper, Jan 17, 2025: “Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations”.
See all 2 papers on probenecid
At a glance
The findings reach worms or flies, none yet in people. 1 lab in 1 country; 17 trials, none about aging, 8 with no results posted.
- 1 lab in 1 country
- 17 trials, none about aging, 8 with no results posted
- Funder: Natural Sciences and Engineering Research Council
What did studies of probenecid find?
1Studies of probenecid measured one outcome, Neuronal efflux transporter activity.
Neuronal efflux transporter activity
downin L. stagnalis1
1 study
Neuronal efflux transporter activity
downin L. stagnalis1
Probenecid inhibits neuronal efflux transporter activity in L. stagnalis (5(6)-carboxyfluorescein removal assay).
“we provide, for the first time, physiological evidence for the existence of probenecid-, MK571- and glutathione-sensitive efflux transporters in (gastropod) neurons”
Model organisms5(6)-carboxyfluorescein removal assayneuron
The Journal of experimental biology
Who is developing probenecid?
3 companies: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Incyte and Guangdong Raynovent Biotech.
Trial sponsors
Iterum Therapeutics, International
Company1 trialPhase 3674 people
Company2 trialsPhase 163 people
Company1 trialPhase 171 people
Company1 trialPhase 149 people
Company1 trialPhase 148 people
Company1 trialPhase 144 people
Company1 trialPhase 140 people
CSPC ZhongQi Pharmaceutical Technology
Company1 trialPhase 128 people